1. G. Gatta, R. Capocaccia, L. Botta, S. Mallone, R. De Angelis, E. Ardanaz, H. Comber, N. Dimitrova, M.K. Leinonen, S. Siesling, J.M. van der Zwan, L. Van Eycken, O. Visser, M.P. Žakelj, L.A. Anderson, F. Bella, I. Kaire, R. Otter, C.A. Stiller, A. Trama RARECAREnet working group, Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. Lancet Oncol., 2017 Aug, 18(8), pp. 1022–1039. 〈https://doi.org/10.1016/S1470-2045(17)30445-X〉. Epub 2017 Jul 4. Erratum in: Lancet Oncol. 2017 Aug;18(8):e433. PMID: 28687376.
2. EUROCARE Working Group. Survival from rare cancer in adults: a population-based study;Gatta;Lancet Oncol.,2006
3. I.Ray-Coquard, E. Pujade Lauraine, A. Le Cesne, P. Pautier, M.C. Vacher Lavenue, A. Trama, P. Casali, J.M. Coindre, J.Y. Blay, Improving treatment results with reference centres for rare cancers: where do we stand? Eur J. Cancer., 2017 May, 77, pp. 90–98. 〈https://doi.org/10.1016/j.ejca.2017.02.006〉. Epub 2017 Apr 3. PMID: 28384534.
4. Rare cancers: a network for better care;Sandrucci;Eur. J. Surg. Oncol.,2019
5. P.K. Mangat, S. Halabi, S.S. Bruinooge, E. Garrett-Mayer, A. Alva, K.A. Janeway, P.J. Stella, E. Voest, K.J. Yost, J. Perlmutter, N. Pinto, E.S. Kim, R.L. Schilsky, Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2018, 2018. 〈https://doi.org/10.1200/PO.18.00122〉. Epub 2018 Jul 11. PMID: 30603737; PMCID: PMC6312096.